ASR Vermogensbeheer N.V. Takes $16.32 Million Position in Illumina, Inc. (NASDAQ:ILMN)

Key Points

• ASR Vermogensbeheer N.V. acquired a $16.32 million stake in Illumina, Inc., purchasing 205,679 shares and holding approximately 0.13% of the company's stock.
• Institutional investors own 89.42% of Illumina's stock, with other significant investors like Capital World Investors and Vanguard Group increasing their stakes considerably in recent quarters.
• Illumina reported $1.19 earnings per share for the latest quarter, beating analysts' expectations, though its revenue of $1.06 billion fell short of estimates and declined by 4.8% year-over-year.

ASR Vermogensbeheer N.V. acquired a new stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 205,679 shares of the life sciences company's stock, valued at approximately $16,318,000. ASR Vermogensbeheer N.V. owned approximately 0.13% of Illumina at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Capital World Investors lifted its stake in shares of Illumina by 408.6% during the fourth quarter. Capital World Investors now owns 18,025,301 shares of the life sciences company's stock worth $2,408,721,000 after purchasing an additional 14,481,232 shares in the last quarter. Vanguard Group Inc. lifted its position in Illumina by 3.5% during the 1st quarter. Vanguard Group Inc. now owns 16,371,662 shares of the life sciences company's stock worth $1,298,928,000 after acquiring an additional 558,243 shares in the last quarter. WCM Investment Management LLC lifted its position in Illumina by 1.2% during the 1st quarter. WCM Investment Management LLC now owns 4,179,011 shares of the life sciences company's stock worth $334,321,000 after acquiring an additional 49,156 shares in the last quarter. Brown Advisory Inc. lifted its position in Illumina by 52.1% during the 1st quarter. Brown Advisory Inc. now owns 2,909,228 shares of the life sciences company's stock worth $230,818,000 after acquiring an additional 996,589 shares in the last quarter. Finally, Northern Trust Corp lifted its position in Illumina by 26.9% during the 4th quarter. Northern Trust Corp now owns 1,652,935 shares of the life sciences company's stock worth $220,882,000 after acquiring an additional 349,878 shares in the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Stephens reissued an "overweight" rating and set a $105.00 target price on shares of Illumina in a research report on Tuesday, May 20th. Royal Bank Of Canada boosted their price objective on shares of Illumina from $118.00 to $126.00 and gave the stock an "outperform" rating in a report on Friday, August 1st. Evercore ISI boosted their price objective on shares of Illumina from $116.00 to $128.00 and gave the stock an "outperform" rating in a report on Tuesday, July 8th. Canaccord Genuity Group boosted their price objective on shares of Illumina from $99.00 to $105.00 and gave the stock a "hold" rating in a report on Friday, August 1st. Finally, Morgan Stanley boosted their price target on Illumina from $100.00 to $105.00 and gave the stock an "equal weight" rating in a research note on Monday. Two analysts have rated the stock with a sell rating, ten have given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $127.47.

Illumina Price Performance

ILMN opened at $97.76 on Wednesday. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.66. The company's 50-day moving average price is $94.47 and its 200 day moving average price is $92.05. The firm has a market cap of $15.03 billion, a price-to-earnings ratio of 12.37, a price-to-earnings-growth ratio of 2.21 and a beta of 1.37. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.17. Illumina had a return on equity of 28.93% and a net margin of 29.36%. The firm had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.12 billion. During the same period last year, the company earned $0.36 earnings per share. The firm's revenue for the quarter was down 4.8% on a year-over-year basis. As a group, sell-side analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current year.

Insider Buying and Selling

In other Illumina news, CFO Ankur Dhingra bought 6,100 shares of the stock in a transaction that occurred on Monday, May 12th. The shares were purchased at an average cost of $81.21 per share, for a total transaction of $495,381.00. Following the transaction, the chief financial officer directly owned 24,906 shares in the company, valued at $2,022,616.26. The trade was a 32.44% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.17% of the stock is currently owned by corporate insiders.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.